link1s.site

Doctors visited the White House 8 times? White House: Biden did not receive treatment for Parkinson's disease

White House spokeswoman Karina Jean-Pierre denied a report in the U.S. media on the 8th that President Joseph Biden did not receive treatment for Parkinson's disease.

Biden had the first televised debate of the 2024 presidential election with Republican opponent Donald Trump on June 27, and his poor performance on the spot triggered discussions about his physical condition. The New York Times reported that a doctor specializing in the treatment of Parkinson's disease had "visited" the White House eight times from August last year to March this year.

Facing the media's questions about Biden's health, Jean-Pierre asked and answered himself at a regular White House press conference on the 8th: "Has the president received treatment for Parkinson's disease? No. Is he currently receiving treatment for Parkinson's disease? No, he is not. Is he taking medication for Parkinson's disease? No."

Jean-Pierre said Biden had seen a neurologist three times, all related to his annual physical examination.

She also took out the report issued by the doctor after Biden's most recent physical examination in February this year. The report said, "An extremely detailed neurological examination was once again reassuring" because no symptoms consistent with stroke, multiple sclerosis or Parkinson's disease were found.

The doctor who went to the White House mentioned by the New York Times is Kevin Kanal, a neurology and movement disorder expert at the Walter Reed National Military Medical Center in Maryland and an authority on Parkinson's disease.

Jean-Pierre suggested that the doctor might have come to treat military personnel on duty at the White House.

OpenAI's internal AI details stolen in 2023 breach, NYT reports
July 4 (Reuters) - A hacker gained access to the internal messaging systems at OpenAI last year and stole details about the design of the company's artificial intelligence technologies, the New York Times reported, opens new tab on Thursday. The hacker lifted details from discussions in an online forum where employees talked about OpenAI's latest technologies, the report said, citing two people familiar with the incident. However, they did not get into the systems where OpenAI, the firm behind chatbot sensation ChatGPT, houses and builds its AI, the report added. OpenAI executives informed both employees at an all-hands meeting in April last year and the company's board about the breach, according to the report, but executives decided not to share the news publicly as no information about customers or partners had been stolen. OpenAI executives did not consider the incident a national security threat, believing the hacker was a private individual with no known ties to a foreign government, the report said. The San Francisco-based company did not inform the federal law enforcement agencies about the breach, it added. OpenAI in May said it had disrupted five covert influence operations that sought to use its AI models for "deceptive activity" across the internet, the latest to stir safety concerns about the potential misuse of the technology. The Biden administration was poised to open up a new front in its effort to safeguard the U.S. AI technology from China and Russia with preliminary plans to place guardrails around the most advanced AI Models including ChatGPT, Reuters earlier reported, citing sources.
TSX futures rise ahead of Fed chair Powell's testimony
July 9 (Reuters) - Futures linked to Canada's main stock index rose on the back of metal prices on Tuesday, while investors awaited U.S. Federal Reserve Chair Jerome Powell's congressional testimony on monetary policy later in the day. The S&P/TSX 60 futures were up 0.25% by 06:28 a.m. ET (1028 GMT). The Toronto Stock Exchange's materials sector was set to re Oil futures , dipped as fears over supply disruption eased after Hurricane Beryl, which hit major refineries along with the U.S. Gulf Coast, caused minimal impact. Markets will be heavily focussed on Powell's two-day monetary policy testimony before the Senate Banking Committee, starting at 10 a.m. ET (1400 GMT), which can help investors gauge the Fed's rate-cut path. Following last week's softer jobs data, market participants are now pricing in a 77% chance of a rate cut by the U.S. central bank in September. The main macro event for the markets this week will be the U.S. consumer prices data due on Thursday, which can help assess the trajectory of inflation in the world' biggest economy. Wall Street futures were also up on Tuesday after the S&P 500 (.SPX), opens new tab and Nasdaq (.IXIC), opens new tab touched record closing highs in the previous session. In Canada, fears of the economy slipping into recession advanced after the latest data showed that the unemployment rate rose to a 29-month high in June. Traders are now pricing in a 65% chance of another cut by the Bank of Canada, which already trimmed interest rates last month. In corporate news, Cenovus Energy (CVE.TO), opens new tab said it is demobilizing some staff at its Sunrise oil sands project in northern Alberta as a precaution due to the evolving wildfire situation in the area.
China proposes to establish BCI committee to strive for domestic innovation
China is mulling over establishing a Brain-Computer Interface (BCI) standardization technical committee under its Ministry of Industry and Information Technology (MIIT), aiming to guide enterprises to enhance industrial standards and boost domestic innovation. The proposed committee, revealed by the MIIT on Monday, will work on composing a BCI standards roadmap for the entire industry development as well as the standards for the research and development of the key technologies involved, according to the MIIT. China has taken strides in developing the BCI industry over the years, not only providing abundant policy support but also generous financial investment, Li Wenyu, secretary of the Brain-Computer Interface Industrial Alliance, told the Global Times. From last year to 2024, both the central and local governments have successively issued relevant policies to support industrial development. The MIIT in 2023 rolled out a plan selecting and promoting a group of units with strong innovation capabilities to break through landmark technological products and accelerate the application of new technologies and products. The Beijing local government also released an action plan to accelerate the industry in the capital (2024-2030) this year. In 2023, there were no fewer than 20 publicly disclosed financing events for BCI companies in China, with a total disclosed amount exceeding 150 million yuan ($20.6 million), Li said. “The strong support from the government has injected momentum into industrial innovation.” The fact that China's BCI industry started later than Western countries such as the US is a reality, leading to the gap in China regarding technological breakthroughs, industrial synergy, and talent development, according to Li. To further close gaps and solve bottlenecks in BCI industrial development, Li suggested that the industry explore various technological approaches to suit different application scenarios and encourage more medical facilities powered by BCI to initiate clinical trials by optimizing the development of BCI-related ethics. Additionally, he highlighted that standard development is one of the aspects to enhance the overall level and competitiveness of the industry chain, which could, in turn, empower domestic BCI innovation. While China's BCI technology generally lags behind leading countries like the US in terms of system integration and clinical application, this has not hindered the release of Neucyber, which stands as China's first "high-performance invasive BCI." Neucyber, an invasive implanted BCI technology, was independently developed by Chinese scientists from the Chinese Institute for Brain Research in Beijing. Li Yuan, Business Development Director of Beijing Xinzhida Neurotechnology, the company that co-developed this BCI system, told the Global Times that the breakthrough of Neucyber could not have been achieved without the efforts of the institute gathering superior resources from various teams in Beijing. A group of mature talents were gathered within the institute, from specific fields involving electrodes, chips, algorithms, software, and materials, Li Yuan said. Shrugging off the outside world's focus on China’s competition with the US in this regard, Li Yuan said her team doesn’t want to be imaginative and talk too much, but strives to produce a set of products step by step that can be useful in actual applications. In addition, Li Wenyu also attributed the emergence of Neucyber to the independent research atmosphere and the well-established talent nurturing mechanism in the Chinese Institute for Brain Research. He said that to advance China’s BCI industry, it is necessary not only to cultivate domestic talents but also to introduce foreign talents to enhance China's research and innovation capabilities. The proposed plan for establishing the BCI standardization technical committee under the MIIT will solicit public opinions until July 30, 2024.
It may be getting harder to leave your smart wearable for the sake of your health
The world's first portable electrocardiograph was an 85-pound backpack, and now a 10-gram patch attached to your chest can transmit electrocardiograms uninterrupted for two weeks. The Apple Watch, which is worn by an estimated 100 million people, can send a text message to alert people when their heartbeat is irregular. Wearable sensors on the arms, wrists and fingers can now report arrhythmias, blood sugar levels, blood oxygen and other health indicators. Medical journals have also proposed a more ambitious vision - wearable devices can monitor patients with chronic diseases, eliminating the need for frequent hospital visits. They can spot potential health problems before a stroke or diabetes develops. The forces of health technology and wearables are converging. Tech giants like Apple (AAPL) and Alphabet's (GOOGL) Google are adding health features to their products. Medical technologists like electrocardiogram patch maker iRhythm Technologies or blood sugar monitor makers DexCom (DXCM) and Abbott Laboratories (ABT) are taking their devices beyond the clinic. "In the sensor world, people started on the consumer side and wanted to get into health care," said Kevin Sayer, chief executive of Decon Medical. "In health care, we're trying to be more consumer oriented, and I think all of those things are sort of colliding." Early bets favored the tech giants, with every health-related announcement from Apple, Google or Samsung Electronics hitting medical tech stocks. But changing doctors' practices will also require sustained investment in clinical trials. Big tech companies have cut back on investments in health care. Now it seems that medical technologists will be at the vanguard of the digital health revolution - with smartwatches and smart rings bringing them more customers who need to be diagnosed. Blake Goodner, co-founder of Bridger Management, a hedge fund focused on health care, said: "A group of medtech companies focused on digital health are maturing and reaching a scale where they can not only be profitable but also make investments to compete with larger tech companies." Tech giants aren't getting out of the health business. Apple's smartwatch has an electronic heart rate sensor that generates a single-point electrocardiogram, a wrist temperature sensor, and an accelerometer that can detect violent falls. Hundreds of millions of people are wearing smartwatches with health features from Apple or its rivals Samsung and Garmin.
Nvidia H20 will sell 1 million units this year, contributing $12 billion in revenue!
Recently, according to the FT, citing the latest forecast data of the market research institute SemiAnalysis, AI chip giant NVIDIA will ship more than 1 million new NVIDIA H20 acceleration chips to the Chinese market this year, and it is expected that the cost of each chip is between $12,000 and $13,000. This is expected to generate more than $12 billion in revenue for Nvidia. Affected by the United States export control policy, Nvidia's advanced AI chip exports to China have been restricted, H20 is Nvidia based on H100 specifically for the Chinese market to launch the three "castration version" GPU among the strongest performance, but its AI performance is only less than 15% of H100, some performance is even less than the domestic Ascend 910B. When Nvidia launched the new H20 in the spring of this year, there were reports that due to the large castration of H20 performance, coupled with the high price, Chinese customers' interest in buying is insufficient, and they will turn more to choose China's domestic AI chips. Then there are rumors that Nvidia has lowered the price of the H20 in order to improve its competitiveness. However, the latest news shows that due to supply issues caused by the low yield of the Ascend 910B chip, Chinese manufacturers in the absence of supply and other better options, Nvidia H20 has started to attract new purchases from Chinese tech giants such as Baidu, Alibaba, Tencent and Bytedance. Analysts at both Morgan Stanley and SemiAnalysis said the H20 chip is now being shipped in bulk and is popular with Chinese customers, despite its performance degradation compared to chips Nvidia sells in the United States.